Identification of an individualized therapy prognostic signature for head and neck squamous cell carcinoma
C Lin, Y Chen, J Pan, Q Lu, P Ji, S Lin, C Liu, S Lin… - BMC genomics, 2023 - Springer
Background Head and neck squamous cell carcinoma (HNSCC) are the most common
cancers in the head and neck. Therapeutic response-related genes (TRRGs) are closely …
cancers in the head and neck. Therapeutic response-related genes (TRRGs) are closely …
Interpretation of Lung Cancer Plasma EGFR Mutation Tests in the Clinical Setting: An Update With Meta-Analysis
AHK Cheung, KY Wong, CH Chiang… - American Journal of …, 2023 - academic.oup.com
Objectives Comprehensive data synthesis of the clinical parameters that affect plasma
EGFR mutation test results in non–small cell lung carcinoma is lacking. Although individual …
EGFR mutation test results in non–small cell lung carcinoma is lacking. Although individual …
云南地区晚期非小细胞肺癌患者的基因突变及其临床意义.
莫欣， 吴茂芳， 蔡静静， 毛佳惠… - Chinese Journal of …, 2021 - search.ebscohost.com
目的: 探讨云南地区晚期非小细胞肺癌(non-small cell lung cancer, NSCLC)
患者外周血中肺癌相关驱动基因突变及其与临床病理特征的关系. 方法: 收集2019 年1 …
患者外周血中肺癌相关驱动基因突变及其与临床病理特征的关系. 方法: 收集2019 年1 …
[PDF][PDF] Prognostic significance of NDRG2 combined with EGFR-sensitizing mutations in lung adenocarcinoma
B Yang, L Ji, Y Feng, XP Li, HG Zhou, T Jiang, T Xiao… - 2020 - scholar.archive.org
Background: N-myc downstream-regulated gene 2 (NDRG2) plays a substantial role in lung
adenocarcinoma (LUAD). Epidermal growth factor receptor (EGFR)-sensitizing mutation …
adenocarcinoma (LUAD). Epidermal growth factor receptor (EGFR)-sensitizing mutation …
[引用][C] Circulating Tumor DNA for Management of Non-Small-Cell Lung Cancer (Liquid Biopsy)
II FoundationOne, IV OncoBEAM, LV OncoBEAM